CCO Slideset

Chronic Myeloid Leukemia

Source: Chronic Myeloid Leukemia*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Chronic Myeloid Leukemia


Program Director: Roy A. Beveridge, MD

Faculty:

  • Charles L. Sawyers, MD
  • Moshe Talpaz, MD

CME CREDIT INFORMATION

Release Date: 03/03/08

Expiration Date: 03/02/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the differences between tyrosine kinase inhibitors and results of recent studies on their use in chronic myeloid leukemia
  • Discuss the clinical implications of data on the use of tyrosine kinase inhibitors in chronic myeloid leukemia
  • Relate the role of genetic analyses in determining treatment options for chronic myeloid leukemia
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.